• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组织因子途径抑制剂-2（TFPI-2）——在癌症和转移中被低估的参与者。

Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.

机构信息

Department of Oncology, Medical University of Bialystok, 12 Ogrodowa, 15-027, Bialystok, Poland.

Department of Clinical Oncology, Comprehensive Cancer Center of Bialystok, 12 Ogrodowa, 15-027, Bialystok, Poland.

出版信息

Cancer Metastasis Rev. 2024 Dec;43(4):1185-1204. doi: 10.1007/s10555-024-10205-7. Epub 2024 Aug 17.

DOI:10.1007/s10555-024-10205-7
PMID:39153052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11554837/
Abstract

The coagulation system is known to play an important role in cancer development and metastasis, but the precise mechanisms by which it does so remain incompletely understood. With this in mind, we provide an updated overview of the effects of TFPI-2, a protease inhibitor, on cancer development and metastasis. TFPI-2 interacts with the thrombin cascade and also employs other mechanisms to suppress cancer growth and dissemination, which include extracellular matrix stabilization, promotion of caspase-mediated cell apoptosis, inhibition of angiogenesis and transduction of intracellular signals. Down-regulation of TFPI-2 expression is well documented in numerous types of neoplasms, mainly via promoter methylation. However, the exact role of TFPI-2 in cancer progression and possible approaches to up-regulate TFPI-2 expression warrant further studies. Strategies to reactivate TFPI-2 may represent a promising direction for future anticancer studies and therapy development.

摘要

凝血系统在癌症的发生和转移中起着重要作用，但凝血系统具体是如何起作用的仍不完全清楚。考虑到这一点，我们提供了一个关于组织因子途径抑制物-2（TFPI-2）对癌症发生和转移影响的最新概述。TFPI-2 与凝血酶级联反应相互作用，还采用其他机制抑制癌症生长和扩散，包括细胞外基质稳定、促进半胱天冬酶介导的细胞凋亡、抑制血管生成和转导细胞内信号。大量研究表明，TFPI-2 在多种类型的肿瘤中表达下调，主要通过启动子甲基化。然而，TFPI-2 在癌症进展中的确切作用以及上调 TFPI-2 表达的可能方法值得进一步研究。重新激活 TFPI-2 的策略可能代表未来癌症研究和治疗发展的一个有前途的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/c52a6b06ab10/10555_2024_10205_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/67d511bad5f9/10555_2024_10205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/f4e8d47b3b0c/10555_2024_10205_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/c52a6b06ab10/10555_2024_10205_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/67d511bad5f9/10555_2024_10205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/f4e8d47b3b0c/10555_2024_10205_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b9/11554837/c52a6b06ab10/10555_2024_10205_Fig3_HTML.jpg

相似文献

1
Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.组织因子途径抑制剂-2（TFPI-2）——在癌症和转移中被低估的参与者。
Cancer Metastasis Rev. 2024 Dec;43(4):1185-1204. doi: 10.1007/s10555-024-10205-7. Epub 2024 Aug 17.
2
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施，以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果：来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
A systematic overview of chemotherapy effects in breast cancer.乳腺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):253-81. doi: 10.1080/02841860151116349.
6
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Short-Term Memory Impairment短期记忆障碍
9
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理：一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

引用本文的文献

1
Tissue Factor Pathway Inhibitor 2 Enhances Hepatocellular Carcinoma Chemosensitivity by Activating CCAR2-GADD45A-Mediated DNA Damage Repair.组织因子途径抑制因子2通过激活CCAR2-GADD45A介导的DNA损伤修复增强肝细胞癌的化疗敏感性。
Int J Biol Sci. 2025 Jul 11;21(10):4629-4646. doi: 10.7150/ijbs.111142. eCollection 2025.
2
Reassessing the Role of Tissue Factor Pathway Inhibitor 2 in Neoplastic and Non-Neoplastic Lesions.重新评估组织因子途径抑制物2在肿瘤性和非肿瘤性病变中的作用
Cancers (Basel). 2025 Apr 25;17(9):1447. doi: 10.3390/cancers17091447.
3
Direct oral anticoagulants do not affect miR-27a-3p expression, a regulator of coagulation cascade, in atrial fibrillation patients.

本文引用的文献

1
Long Non-Coding RNAs: Tools for Understanding and Targeting Cancer Pathways.长链非编码RNA：理解和靶向癌症通路的工具
Cancers (Basel). 2022 Sep 29;14(19):4760. doi: 10.3390/cancers14194760.
2
Tissue factor pathway inhibitor 2: A potential diagnostic marker for discriminating benign from malignant ovarian tumors.组织因子途径抑制剂 2：鉴别良恶性卵巢肿瘤的潜在诊断标志物。
J Obstet Gynaecol Res. 2022 Sep;48(9):2442-2451. doi: 10.1111/jog.15345. Epub 2022 Jul 1.
3
MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2.
直接口服抗凝剂不会影响房颤患者体内凝血级联反应调节因子miR-27a-3p的表达。
J Thromb Thrombolysis. 2025 Jun;58(5):636-645. doi: 10.1007/s11239-025-03102-5. Epub 2025 Apr 21.
4
Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma.组织因子途径抑制剂 2（TFPI2）是透明细胞肾细胞癌的一种潜在血清生物标志物。
Sci Rep. 2024 Nov 19;14(1):28639. doi: 10.1038/s41598-024-80248-x.
MBD3 通过负向调控肿瘤抑制因子 TFPI2 促进肝癌的进展和转移。
Br J Cancer. 2022 Sep;127(4):612-623. doi: 10.1038/s41416-022-01831-5. Epub 2022 Apr 30.
4
mA RNA demethylase FTO promotes the growth, migration and invasion of pancreatic cancer cells through inhibiting TFPI-2.mA RNA 去甲基酶 FTO 通过抑制 TFPI-2 促进胰腺癌细胞的生长、迁移和侵袭。
Epigenetics. 2022 Dec;17(12):1738-1752. doi: 10.1080/15592294.2022.2061117. Epub 2022 Apr 11.
5
The methylation of SDC2 and TFPI2 defined three methylator phenotypes of colorectal cancer.SDC2 和 TFPI2 的甲基化定义了三种结直肠癌甲基化表型。
BMC Gastroenterol. 2022 Feb 28;22(1):88. doi: 10.1186/s12876-022-02175-3.
6
TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy.TFPI2 抑制 TGF-β2 通路调节剂的相互作用，促进糖尿病肾病中的血管内皮-间充质转化。
J Biol Chem. 2022 Mar;298(3):101725. doi: 10.1016/j.jbc.2022.101725. Epub 2022 Feb 11.
7
MEG8 regulates Tissue Factor Pathway Inhibitor 2 (TFPI2) expression in the endothelium.MEG8 调控内皮细胞组织因子途径抑制物 2（TFPI2）的表达。
Sci Rep. 2022 Jan 17;12(1):843. doi: 10.1038/s41598-022-04812-z.
8
Folate-Targeted pH and Redox Dual Stimulation-Responsive Nanocarrier for Codelivering of Docetaxel and TFPI-2 for Nasopharyngeal Carcinoma Therapy.用于鼻咽癌治疗的多西他赛和TFPI-2共递送的叶酸靶向pH和氧化还原双刺激响应纳米载体
ACS Appl Bio Mater. 2019 May 20;2(5):1830-1841. doi: 10.1021/acsabm.8b00675. Epub 2019 May 8.
9
The prognostic value of lncRNA AGAP2-AS1 in cancer patients: A meta-analysis.lncRNA AGAP2-AS1 在癌症患者中的预后价值：一项荟萃分析。
Medicine (Baltimore). 2021 Dec 23;100(51):e28425. doi: 10.1097/MD.0000000000028425.
10
TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1.TMPRSS4 通过 SLUG 和 TWIST1 上调 SOX2 促进前列腺癌细胞中的癌症干细胞样特性。
J Exp Clin Cancer Res. 2021 Nov 22;40(1):372. doi: 10.1186/s13046-021-02147-7.